Monday, October 29, 2012
Galena Biopharma Inc., of Lake Oswego, Ore., said data from a Phase I/II study showed that NeuVax (nelipepimut-S or E75) decreased circulating tumor cells in 16 of 26 breast cancer patients during vaccine treatment.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.